Nebenwirkungen · Taltz
Taltz 80 mg solution for injection in pre-filled pen · Abschnitt 4.8 · PDF-Seite 42
HOS-133089 · Präparat HOS-097358
The majority of infections were non-serious and mild to moderate in severity, most of which did not necessitate treatment discontinuation. Serious infections occurred in 13 (0.6 %) of patients treated with Taltz and in 3 (0.4 %) of patients treated with placebo (see section 4.4). Over the entire treatment period infections were reported in 52.8 % of patients treated with Taltz (46.9 per 100 patient years). Serious infections were reported in 1.6 % of patients treated with Taltz (1.5 per 100 patient years).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-23T15:10:00Z · SHA-256 f449380f0849b33ad619f5ae5676924bf717d85b4fc30ce625002744eb8359ab · Passage ecb90ff4fce7ebba1f35c718bd3744871e900ca57700e6cab571806332787bd6 · Zeichen 5565–6076 im Abschnitt